A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
Cervical Cancer|Microsatellite Instability (MSI)-High Endometrial Cancer|Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])|Esophageal Cancer|Hepatocellular Carcinoma|Melanoma (Uveal Melanoma Excluded)|Merkel Cell Carcinoma|Mesothelioma|MSI-high Colorectal Cancer|Non-small Cell Lung Cancer (NSCLC)|Ovarian Cancer|Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Small Cell Lung Cancer (SCLC)|Renal Cell Carcinoma (RCC)|Triple-negative Breast Cancer|Urothelial Carcinoma|Diffuse Large B-cell Lymphoma
BIOLOGICAL: INCAGN02385
Number of treatment-emergent adverse events (TEAEs), TEAE defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug., Up to 12 months
Cmax of INCAGN02385, Maximum observed plasma concentration., Up to 12 months|Tmax of INCAGN02385, Time to maximum plasma concentration., Up to 12 months|Cmin of INCAGN02385, Minimum observed plasma concentration during the dosing interval., Up to 12 months|AUC0-t of INCAGN02385, Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration., Up to 12 months|Objective response rate (ORR) in participants with advanced or metastatic solid tumors, Defined as the percentage of participants having complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1., Up to 12 months|Disease control rate (DCR) in participants with advanced or metastatic solid tumors, Defined as percentage of participants having CR, PR, or stable disease (SD) as best on-study response., Up to 12 months|Duration of response (DOR) in participants with advanced or metastatic solid tumors, Defined as the time from earliest date of disease response (CR or PR) until earliest date of disease progression per RECIST v1.1 or death from any cause, if occurring sooner than progression., Up to 12 months|Progression-free survival (PFS) in participants with advanced or metastatic solid tumors, Defined as the time from date of first dose of study drug until the earliest date of disease progression per RECIST v1.1 or death from any cause if occurring sooner than progression., Up to 12 months|ORR in participants with diffuse large B-cell lymphoma (DLBCL), Defined as the percentage of participants with a CR/complete metabolic response (CMR) or PR/partial metabolic response (PMR) per the Lugano Classification., Up to 12 months|DOR in participants with DLBCL, Defined as the time from first documented evidence of CR/CMR or PR/PMR until disease progression per radiographic disease assessment or death from any cause among participants who achieve an objective response., Up to 12 months|PFS in participants with DLBCL, Defined as the time from the date of the first dose of study drug until the earliest date of disease progression per radiographic disease assessment or death from any cause if occurring sooner than progression., Up to 12 months
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.